Levosulpiride Induced Parkinsonism and Other Movement Disorders

Aravind Gowtham1, Bahiya Sulthana1, Dhanya Sacheendran2 and Sujith Ovallath1*

1James Parkinson’s Movement disorder Research Centre, Kannur Medical College, India
2Department of Pharmacology, Kannur Medical College, India

Submission: July 20, 2017; Published: August 21, 2017

*Corresponding author: Sujith Ovallath, Professor and Head of Neurology, Director, James Parkinson’s Movement disorder research centre, Kannur Medical college, Kerala, India; Email: sujithok@gmail.com

Abstract

Drug induced Parkinsonism; the second leading cause of Parkinsonism remains often under recognised. Main culprits like neuroleptics get scrutinized while drugs like levosulpiride go unsupervised many a time. Levosulpiride is an enantiomer of the sulphiride with antidopaminergic activity at D2 receptor and agonistic activity at 5HT4 receptors. Due to inhibition of F2 receptors in the gastrointestinal system, there is increased gastric and gall bladder mobility as well as increased tone of lower esophageal sphincters. Central action at area postrema also renders helping hand as a potent antiemetic. It’s used in dyspepsia, gastroparesis, burning mouth syndrome, cataplexy, acute labyrinthine dysfunction, glycemic control and premature ejaculation. Psychiatric illness such as depressive disorders, somatiform disorder and positive as well as negative symptoms in schizophrenia recommends levosulpiride use. Drug remains unmetabolised and excreted in urine unchanged which reduces the drug interactions. No teratogenic, mutagenic or oncogenic potential are found in animal experiments but no studies have been confident about its use in pregnancy. As the drug is excreted in breast milk it’s highly advised to be restricted in lactating mothers.

Non- motor side effects include Sedation or drowsiness, hyperprolactinemia, postural hypotension, weight gain, QT prolongation and elevated liver transaminases have been reported. Motor side effect includes Parkinsonism, tardive dyskinesia, isolated tremors, orolingual dyskinesia, hemichorea and acute muscular dystonias with most common being Parkinsonism with ever rising incidence. Levosulpiride induced parkinsonism is mostly reversible condition upon cessation of the drug while sometimes the symptom complex persist indicating underlying dopaminergic dysfunction unmasked at an earlier occasion. Any patient presenting with parkinsonian features all and any drug the patient is on can be a potential culprit. Possible offenders can be halted for a while and reassessment will help in differentiating clinically. Investigation like MRI, SPECT will help in differentiating the levosulpiride induced Parkinsonism from idiopathic parkinson’s disease. Hence it is imperative for primary care physicians to be involved in pharmacovigilance of Levosulpiride and any drugs, so as to ensure do more good than harm.

Keywords: Levosulpiride; Drug induced parkinsonism

Introduction

Drug induced Parkinsonism (DIP) is now the second leading cause of Parkinsonism behind idiopathic Parkinson’s disease. DIP can be defined as reversible development of parkinsonian syndrome in patients treated with drugs which impair dopamine function [1]. However some drugs uncover a dormant dopaminergic pathway abnormality leading to full blown Parkinsonism. Many commonly prescribed safe drugs for common diseases are being reported to interfere with dopaminergic and cholinergic pathways causing classical parkinsonian manifestations. Movement disorders like tardive dyskinesia, tardive dystonia, akathisia, myoclonus, tremors are the commonly observed disorders with an offending drug as the etiological factor. Failure in identifying the drugs causing Parkinsonism, results in refractory symptoms with frequent outpatient/ inpatient visits forcing an economic burden and untold morbidity on the patient’s part. A community-based survey and a population-based study found DIP prevalence rates of 2.7% and 1.7%, respectively, whereas those of PD were 3.3% and 4.5%, respectively. However, 6.8% of the patients diagnosed with PD were later reclassified as having DIP [2]. This survey, thus reiterates the challenge of identifying the drugs impairing the dopaminergic pathway. The common culprits include neuroleptics such as chlorpromazine and clozapine, anti emetics such as metoclopramide and calcium channel blockers which are properly scrutinized after prescription. However, the repercussions of using Levosulpiride as a prokinetic drug are being brought to light recently. Levosulpiride, a selective dopamine D2-receptor antagonist, though appears as a seemingly harmless adjunct prescribed to a minor complaint, may end up being detrimental to the patient.
Levorotatory enantiomer of sulpiride, Levosulpiride is a benzamide derivative that selectively inhibits the dopamine D2 receptor in the central nervous system (CNS) and in the gastrointestinal (GI) tract. It’s biologically more potent and better tolerated when compared to its counterpart isomer and racemic sulpiride [3]. Developed in Ravizza Farmaceuttici S.p.A Italy; it has captured attention of many practitioners in few years out in market and also insinuated into many successful combinations. Classified into classes such as prokinetic agent, antidepressant and antipsychotic made its way into numerous prescriptions.

Levosulpiride selectively inhibits D2 receptors with moderate agonistic action on 5-HT4 receptor. Action at D2 receptors occurs in both central and periphery. Neuronal and muscular D2 receptor blockade in the gastrointestinal system asserts the prokinetic action while central inhibition of D2 receptors especially in the area postrema exerts antiemetic property. Central inhibitions also bring about unnecessary adverse reaction like hyperprolactinemia and dystonias. Action on 5HT4 receptors in cholinergic neurons releases acetylcholine which further promotes its prokinetic activity [4]. Several studies proved the efficacy of Levosulpiride in reducing the gastric emptying time to be more than placebo [5] (BS) and almost equivalent to that to cisapride [6] and domperidone [7] using various modalities like ultrasonography, radiology, scintigraphy, electrical impedance, intracavitary manometric monitoring and 13C-octanoic breath test. Normalizing the gastric electrical activity [8] and enhancement of gastric motility in both fed and fasting states [9] brought about relief to patients with functional dyspepsia. Levosulpiride also enhances gallbladder transit time, reduces gallbladder volume [10] and increases tone of lower esophageal sphincter [11]. Levosulpiride exhibits linear pharmacokinetics with bioavailability being more after intramuscular administration than tablets and oral solution (drops) [12]. The plasma t1/2 of the drug is about 6-8 hours. Drug remains unmetabolised and excreted in urine unchanged. Interaction with other drugs remains highly unlikely due to lack of hepatic metabolism. In animal studies conducted, levosulpiride showed low reproduction toxicity, mutagenic potential and oncogenic/carcinogenic potential in doses higher than normally used. It also doesn’t demonstrate any toxicity from accumulation, tolerance, dependence or withdrawal syndrome [13].

**Indications**

Levosulpiride, as an atypical neuroleptic is beneficial in schizophrenia. At low doses, it binds to presynaptic receptors causing reduction in dopamine levels, while acting as an antagonist at postsynaptic receptors at higher doses. This property is useful in controlling both the positive and negative symptoms. It also has the therapeutic advantage of being an antidepressant at lower doses. Levosulpiride is used in the treatment of patients with refractory dyspepsia, i.e. in which proton pump inhibitors yielded no relief, upper Gl endoscopy was normal and no evidence of *H. pylori* infection [14].

Withdrawal of cisapride from market in 2000 because of its cardiovascular adverse effect [15], aroused interest for the search of alternatives treatment for the management of functional dyspepsia [16]. Levosulpiride being a suitable alternative, controls gastro intestinal motility through its action on dopaminergic and serotonergic pathways. The symptoms related to gastric emptying pattern like epigastric discomfort, postprandial fullness and bloating, while nausea, vomiting and early satiety are more improved with levosulpiride treatment [17] Levosulpiride has been demonstrated to improve glycemic control by improving gastric motility in type 1 diabetes mellitus without any change in insulin dosage [18]. This could be explained by a better synchronization between the onset of exogenous insulin and release of nutrients from the stomach into the intestine and their absorption in the general circulation [18]. The study finding supported the role of gastric emptying in maintaining glycemic control in IDDM patients [18]. Since DA seems to have a role in facilitating sexual arousal and in lowering the ejaculatory threshold, DA antagonists like levosulpiride are likely to have an inhibitory function and has been proved to be effective in premature ejaculation [19].

A double blind study of levosulpiride in patients with somatoform disorders showed benefit after 6 weeks [20]. Levosulpiride has also been used successfully in patients with burning mouth syndrome. A study conducted on 44 subjects suffering from idiopathic burning mouth syndrome revealed that levosulpiride was more effective in patients who have recently developed burning/ stinging oral sensation [21]. Levosulpiride has demonstrated promising prospects in the treatment of cataplexy in animal models with an added privilege of non reduction of the REM sleep [22]. Levosulpiride has been used with varying success in unilateral labyrinthine dysfunction as it has been shown to reduce the recurrence of attacks [23].

**Adverse Effects**

Levosulpiride is used widely in several Asian and European countries to treat nausea, vomiting, and functional dyspepsia. Levosulpiride, being a neuroleptic agent is known to cause drowsiness as a result of reducing afferent signals to the reticular activating system. Though to a lesser extent than other antipsychotics, it has, nevertheless, been known to cause neuroleptic malignant syndrome constituted by hyperpyrexia and muscle rigidity, leading to muscular damage. Effects on the pituitary gland situated outside the blood brain barrier lead to weight gain; raised plasma prolactin levels causing breast enlargement, mastalgia and lactation, which are attributed to the virtue of dopaminergic antagonism, these side effects can be avoided with lower dosages. Tolerance develops to autonomic consequence such as postural hypotension. Generally, domperidone is considered to be safe for the management of GI discomfort, even in patients with PD, because it does not cross

---

**How to cite this article:** Aravind G, Bahiya S, Dhanya S, Sujith Ovallath. Levosulpiride Induced Parkinsonism and Other Movement Disorders. Open Access J Neurol Neurosurg. 2017; 5(3): 555665. DOI: 10.19080/OAJNN.2017.05.555665.
the blood-brain barrier [24]. Thus, prescribing levosulpiride to the geriatric and pediatric patients is harmful and is best avoided in the two age groups.

A case of QT prolongation has been reported when levosulpiride was administered to a patient on citalopram for reactive depression [25]. Levosulpiride may act as a moderate antagonist at 5-HT3 receptors as well as a moderate agonist at serotonin 5-HT4 receptors. In addition, it has, at least in part, similar effects as the benzamide derivative cisapride, which also possesses class III antiarrhythmic activity [26]. Citalopram is a selective serotonin reuptake inhibitor that is used for the treatment of major depression, with a better cardiac safety profile than tricyclic antidepressants [27]. Conclusion was drawn that levosulpiride may express partial 5-HT4 receptor agonist activity also at the ventricular level, thus favoring the development of electrical storm if an underlying proarrhythmic mechanism is present, as occurred with citalopram-induced QT prolongation in the patient [25].

Veralipride, another benzamide derivative is frequently being used as an alternative to hormonal therapy due to its generally well tolerated effect on menopause-related symptoms [28,29]. The central nervous system effects of veralipride, especially on the hypothalamus, are described as secondary to hyperprolactinaemia, either as a feedback in tuberoinfundibular dopamine neurons or secondary to an opioid agonistic effect [30]. The parkinsonian syndrome was described as a case report by Milandre et al. [31] and Franghignoni and Tesio in 1995. Masmoudi et al. [32], also reported on a parkinsonian syndrome, adding four other veralipride-induced dyskinesia [32]. An instance of worsening of parkinsonian symptoms on consumption of veralipride has been reported. The patient who was diagnosed to have Idiopathic Parkinson's Disease (IPD), previously responsive to levodopa, presented with worsening of rigidity, bradykinesia, which, after the withdrawal of veralipride, returned to the baseline [33].

Even though the occurrence of Levosulpiride Induced Movement disorder (LIM) is rare in patients with normal kidney function, Levosulpiride induced Movement disorders occurs much more commonly in chronic kidney disease patients contrary to the belief. Hence the dose of levosulpiride should be modified in patients with chronic kidney disease [34]. Other contraindications include known epilepsy, porphyrias, tumours like prolanctoma, pheochromocytoma and carcinoma breast, alcoholic intoxication. The drug is known to be secreted in breast milk, so, its use should be restricted in breastfeeding women [35].

Levosulpiride induced parkinsonism and other movement disorders

Case vignette: A 72yr old male with a history of coronary artery disease, type 2 diabetes mellitus, essential hypertension, dyslipidemia for which he was on regular medications, presented with complaints of tremors in his right hand. The resting tremors gradually and progressively involved all the four limbs, prominently observed in the lower limbs with associated rigidity, impairing his ability to carry out his routine activities. Physical examination revealed the presence of orolinguuid tremors, hypophonia, impassive face, stooped posture, positive glabellar tap and shuffling gait suggestive of parkinsonism. The patient had been prescribed a combination of pantoprazole with Levosulpiride for gastritis for the past 1year. On discontinuation of Levosulpiride for 2weeks, there was considerable reversal of symptoms, as evidenced by the improvement in his UPDRS score from 48 to 13.

Until recently, the drug-induced movement disorders related to levosulpiride were under-recognized, but it has now been shown that levosulpiride frequently causes Parkinsonism [36]. Extrapyramidal effects by levosulpiride is based on the affinity constants for the D2 receptors. Dopaminergic antagonism at the pre synaptically and post synthetically present D2 and D3 results in increased involuntary movement which is manifested as tardive dyskinesia. Tardive dyskinesia is observed late in therapy as rhythmical facial and oral movements. Levosulpiride has also been reported to cause acute muscular dystonia of hands, leg, tongue muscles and akathesia [35]. Other motor manifestations include rhythmic sinusoidal oscillation of the anterior upper neck.

One of the studies concerning Levosulpiride induced movement disorders, revealed that levosulpiride induced disabling parkinsonism or severe oro-lingual dyskinesia in many patients; 21(24.7%) of the 85 patients with LIP were rated as Hoehn and Yahr stage III-V and all 9 patients with oro-lingual dyskinesia had severe difficulties in speech and chewing [36]. In a study comprising 132 patients with drug-induced movement disorders, 91 were exposed to levosulpiride The most common levosulpiride-induced movement disorder was Parkinsonism (93.4%), followed by tardive dyskinesia (9.9%), and isolated tremor (3.3%). The study also noted that 48.1% of the patients with LIP did not improve after withdrawing the drug [37]. There have been a few instances of hemichorea induced by Levosulpiride. The underlying mechanism is largely believed to be striatal dysfunction as evidenced by hypoperfusion of basal ganglia on Brain SPECT [38].

Management

The clinical diagnostic criteria for DIP are defined as 1) the presence of parkinsonism, 2) no history of parkinsonism before the use of the offending drug, and 3) onset of parkinsonian symptoms during use of the offending drug [36]. Thus, reversible LIM may be defined as the complete absence of abnormal involuntary movement after cessation of levosulpiride. Irreversible LIM may be defined as the persistence or recurrence
of the abnormal involuntary movements after discontinuation of levosulpiride, or other medication used to treat LIM [36]. A detailed neurological and psychological assessment plays a crucial role in classification of severity of the disability. UPDRS, Hoehn and Yahr stage and symmetry of Parkinsonism and psychological questionnaires are useful tools in diagnosing as well as gauging the recovery.

Studying normal MRI and F-FIP-PET scans of parkinsonian patients has revealed the fact that DIP caused by prokinetic drugs, is a result of anatomical changes such as increased right cerebellar cortical volume, areas of cortical thinning in subcortical structures which lead to cognitive dysfunction. Conversely, a higher prevalence of DIP in patients with cognitive dysfunction suggests that cognitive dysfunction itself may be a risk factor [39]. DATs are presynaptic proteins which regulate the dopaminergic transmission. The dopaminergic nigrostriatal pathway can be imaged by employing DAT ligands by Single Photon Emission Computed Tomography (SPECT). SPECT radioligands include 123I-N-3-fluoropropyl-2β-carbomethoxy-3β-(4iodophenyl)nortropane (123I-FP-CIT or 123I-β-CIT-FP), 123Iioflupane, DaTSCAN, and 123I-2β-carbomethoxy-3β-(4iodophenyl)tropane (123I-β-CIT). PET scans may be superior to SPECT for imaging DATs, in that the lower energy of positrons provides higher resolution, resulting in better image quality with widespread clinical applications. DAT scans may show symmetric uptake of radiotracer in the bilateral striatum in patients with pure DIP, even if they have significant Parkinsonism [40]. Thus DAT scans are helpful in distinguishing PD uncovered by the drug from pure DIP. DAT imaging can also be employed to determine the clinical course of DIP patients.

In a study, among the 85 patients with LIP, 52 were clinically assessed at one year postdiagnosis: LIP in 27 patients (51.9%) was reversible, whereas it was irreversible in others; In the 27 patients with reversible LIP, the mean interval from cessation of levosulpiride to disappearance of Parkinsonism was 3.4±2.4 months [36]. Identification and discontinuation of the offending drug leads to reversal of symptoms within weeks to months. However Parkinsonism may persist or progress in 10-50% of the patients [40].

Conclusion

Levosulpiride induced parkinsonism is often under recognized possibly due to unawareness of the condition. It has been shown that almost half of the patients diagnosed with levosulpiride induced Parkinsonism progress to irreversible Parkinsonism. A drug used for relatively trivial condition leading on to a chronic disabling disorder warrants urgent attention. A clear cut warning on the drug envelope is warranted. The treating physician should look for early pyramidal side effects and stop the drug on slightest suspicion of such symptoms or signs increasing the awareness among doctors about the risk of using this drug injudiciously must be carried out on an urgent basis.

References

1. Bahiya S, Sujith O (2017) Drug induced Parkinsonism: an overview. Open Access J Neurol Neurosurg 3(4): 555620.
2. Shin HW, Chung SJ (2012) Drug-induced Parkinsonism. J Clin Neurol 8(1): 15-21.
3. Mucci A, Nolfe G, Maj M (1995) Levosulpiride: a review of its clinical uses in psychiatry. Pharmacol res 31(2): 95-101.
4. Tonini M (1996) Recent advances in the pharmacology of gastrointestinal prokinetics. Pharmacological Res 33(4-5): 217-226.
5. Arruti V, Coraza GR, Sorge M, Boriani L, Ugenti F, et al. (1994) The effects of levosulpiride on gastric and gall-bladder emptying in functional dyspepsia. Alimentary pharmacology & therapies 8(6): 631-638.
6. Mansi C, Savarino V, Remagnino A, Borro P, Mele MR, et al. (1998) Comparison of the gastrokinetic effect of cisapride and levosulpiride on fat-induced delayed gastric emptying. Gastroenterology 114: A213.
7. Mangiameli A, Brogna A, Catanzaro R, Sofia M, Basli S (1994) Levosulpiride vs domperidone nel trattamento della dispepsia funzionale. Clinica terapeutica 144(2): 107-114.
8. Bazzocchi G, Diquattro C, Conti E, Balloni M, Reddy SN, et al. (1998) Effect of levosulpiride on electrogastrogram in patients with functional dyspepsia. Gastroenterology 114: A719.
9. Pasaretti S, Mazzotti G, Fronzoni M (1992) Motilita antroudeodenale nella dispepsia non organica. Gli Specializzati Oggi Gastroenterologia 1(Suppl 2): 15-19.
10. Mansi C, Savarino V, Vigneri S, Sciaba L, Perilli D, et al. (1995) Effect of D2-dopamine receptor antagonist levosulpiride on diabetic cholecystoaplasia: a double-blind crossover study. Alimentary pharmacology & therapeutics 9(2): 185-189.
11. Sabbatini F, Petrelli G, La Manna S, Russo T, Lobello R, et al. (1989) The effect of L-sulpiride on lower esophageal sphincter pressure and esophageal peristaltic activity in healthy subjects. Current therapeutic research 46(3): 445-451.
12. Xu M, Zhou Y, Ni Y, He X, Li H, et al. (2015) Tolerance and Pharmacokinetic Comparison of Oral, Intramuscular, and Intravenous Administration of Levosulpiride After Single and Multiple Dosing in Healthy Chinese Volunteers. Clinical therapeutics 37(11): 2458-2467.
13. Rossi F, Forgione A (1995) Pharmacotoxicological aspects of levosulpiride. Pharmacol Res 31(2): 81-94.
14. Harmon RC, Peura DA (2010) Evaluation and management of dyspepsia. Therap Adv Gastroenterol 3(8): 87-98.
15. US Food and Drug Administration (2000) FDA talk paper. Janssen Pharmaceutical stops marketing cisapride in the US.
16. Mearin F, Rodrigo L, Pérez-Mota A, Balboa A, Jiménez L, et al. (2004) Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. Clin Gastroenterol Hepato12: 301-308.
17. Mansi C, Borro P, Giacomini M, Biagini R, Mele MR, et al. (2000) Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 14(5): 561-569.
18. Melga P, Mansi C, Ciuchi E, Giusti R, Sciaba L, et al. (1997) Chronic administration of levosulpiride and glycemic control in IDDM patients with gastroparesis. Diabetes Care 20: 55-58.
19. E Greco, P Polonio-Balti, Speranza JC (2002) Levosulpiride: a new solution for premature ejaculation? Int J Impot Res 14: 308-309.

How to cite this article: Aravind G, Bahiya S, Dhanya S, Sujith Ovallath. Levosulpiride Induced Parkinsonism and Other Movement Disorders. Open Access J Neurol Neurosurg. 2017; 5(3): 555665. DOI: 10.19080/OAJNN.2017.05.555665.
20. Altamura AC, Mauri MC, Regerazziti G (1991) L-sulpiride in the treatment of somatoform disturbances: a double blind study with racemic sulpiride. Neuripsychiatr 32: 25-29.

21. Demans F, Tarozzi M, Lodi G, Canegallo L, Rimondini L, et al. (2007) The effect of levosulpiride in burning mouth syndrome. Minerva stomatol 56(1-2): 21-26.

22. Okura M, Reihl J, Mignot E, Nishino S (2000) Sulpiride, a D2 /D3 blocker reduces cataplexy but not REM sleep in canine narcolepsy. Neuropsychopharmacology 23(5): 528-38.

23. Zanetti D, Civiero N, Balzanelli C, Tonini M, Antonelli AR (2004) Improvement of vestibular compensation by Levo-sulpiride in acute unilateral labyrinthine dysfunction. Acta Otorhinolaryngol Ital 24: 49-57.

24. Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, et al. (2004) Clinical implications of enteric and central D2 receptor blockade by antipsychomatic gastrointestinal prokinetics. Alimentary Pharmacology & Therapeutics 19(4): 379-390.

25. Agosti S, Casalino L, Bertero G, Burrone A, Brunelli C, et al. (2013) Citalopram and levosulpiride: a dangerous drug combination for QT prolongation. The American journal of emergency medicine 31(11): 1624.

26. Tonini M, De Ponti F, Di Nucci A, Crema F (1999) Cardiac adverse effects of gastrointestinal prokinetics. Alimentary Pharmacology & Therapeutics 19(12): 1585-1591.

27. Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, et al. (2013) QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 346:f288.

28. David A, Don R, Tajchler G, Weissglas L (1988) Venlafaxine: alternative antidepressant treatment for menopausal symptoms. American journal of obstetrics and gynecology 158(5): 1107-1115.

29. Wessels, Bosuma WB (1983) The alternative to hormonal treatment of menopausal vasomotor flushes: veralipride. La semaine des hopitaux: organe fonde par l'Association d'enseignement medical des hopitaux de Paris 59(9): 596-599.

30. Zichella L, Falaschi P, Fioretti P, Melis GR, Cagnacci A, et al. (1986) Effects of different dopamine agonists and antagonists on post-menopausal hot flushes. Maturitas 8(3): 229-237.

31. Milandre L, Ali CA, Khalil R (1991) Parkinsonism syndrome during a treatment with veralipride. La Revue de médecine interne/fondée par la Société nationale française de médecine interne 12(2): 157.

32. Masmoudi K, Decoq G, Chetaille E, Rosa A, Mizon JP, et al. (1994) Extrapyramidal disorders induced by veralipride (Agreal). Apropos of 5 cases. Therapie 50(5): 451-454.

33. Teive HA, Sa DS (2001) Worsening of parkinsonism after the use of veralipride for treatment of menopause: case report. Arquivos de neuro-psiquiatria 59(1): 123-124.

34. Srinivas prasad ND, Chandramohan G, Gopalane S, Fernando BEM, et al. (2016) Levosulpiride use in chronic kidney disease patients—Do we need to be cautious? JOSR-JDMS 15(9): 150-155.

35. Gupta S, Garg GR, Halder S, Sharma KK (2007) Levosulpiride: A Review.

36. Shin HW, Kim MJ, Kim JS, Lee MC, Chung SJ (2009) Levosulpiride-induced movement disorders. Mov Disord 24(15): 2249-2253.

37. Mathew T, Nadimpally US, Prabhu AD, Nadig R (2017) Drug-induced Parkinsonism on the rise: Beware of levosulpiride and its combinations with proton pump inhibitors. Neurol India 65(1): 173-174.

38. Lee HC, Hwang SH, Kang SY (2016) Levosulpiride-Associated Hemichorea. Yonsei medical journal 57(3): 803-805.

39. Ahn HJ, Yoo WK, Park J, Ma HI, Kim YJ (2015) Cognitive dysfunction in drug-induced parkinsonism caused by prokinetics and antiemetics. J Korean Med Sci 30(9): 1328-1333.

40. Varrone A, Halfin C (2010) Molecular imaging of the dopamine transporter. J Nucl Med 51(9): 1331-1334.